 Despite the recent selloff, shares of Revance Therapeutics are up 65 since I gave a very bullish recommendation 2 years ago. In that time, we have have seen an equity raise, acquisition of sales rights for RHA fillers from Teoxane, a convertible note offering and of course the COVID-19 pandemic. 